Fmr LLC Cuts Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

FMR LLC trimmed its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 51.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 104,334 shares of the life sciences company's stock after selling 110,076 shares during the quarter. FMR LLC owned 0.14% of Integra LifeSciences worth $1,896,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Versor Investments LP bought a new position in Integra LifeSciences in the 3rd quarter valued at $612,000. GSA Capital Partners LLP bought a new stake in shares of Integra LifeSciences in the third quarter valued at $960,000. Point72 Europe London LLP lifted its holdings in Integra LifeSciences by 13.8% during the second quarter. Point72 Europe London LLP now owns 546,035 shares of the life sciences company's stock valued at $15,911,000 after purchasing an additional 66,400 shares during the last quarter. Public Sector Pension Investment Board purchased a new position in Integra LifeSciences in the 2nd quarter valued at approximately $4,395,000. Finally, State of Alaska Department of Revenue raised its holdings in Integra LifeSciences by 144.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 131,751 shares of the life sciences company's stock valued at $2,393,000 after acquiring an additional 77,825 shares during the period. Institutional investors own 84.78% of the company's stock.

Insider Buying and Selling

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the firm's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now owns 56,182 shares of the company's stock, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.10% of the stock is currently owned by corporate insiders.

Integra LifeSciences Stock Performance

Shares of IART stock traded down $0.32 during mid-day trading on Monday, reaching $23.71. 544,807 shares of the company's stock traded hands, compared to its average volume of 1,062,534. The firm has a market capitalization of $1.83 billion, a PE ratio of -267.00, a price-to-earnings-growth ratio of 0.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The firm has a 50 day moving average price of $22.12 and a two-hundred day moving average price of $23.69. Integra LifeSciences Holdings Co. has a 12 month low of $16.81 and a 12 month high of $45.42.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. During the same quarter in the prior year, the business earned $0.76 earnings per share. Integra LifeSciences's revenue for the quarter was down .4% on a year-over-year basis. On average, research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on IART shares. BTIG Research upgraded Integra LifeSciences from a "sell" rating to a "neutral" rating in a research note on Monday, October 7th. Truist Financial decreased their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a research report on Monday, October 14th. Citigroup raised their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a research report on Tuesday, November 5th. Bank of America lowered their price target on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating on the stock in a research report on Monday, October 7th. Finally, Morgan Stanley assumed coverage on Integra LifeSciences in a research note on Monday, December 2nd. They issued an "underweight" rating and a $20.00 target price for the company. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $23.00.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.